Hepatitis is mainly the swelling of Liver; it is a kind of infection that gives way to acute diseases like liver cancer which results in the transplantation of liver. It has different levels wherein Hepatitis C is the most common form of Hepatitis caused by HCV. It usually spreads with a direct contact of an infected person e.g., by having intercourse or infected blood transfer or by an infected person giving birth.
Symptoms of Hepatitis C are pains in muscle, Yellowish Eyes and Skins. This disease is contagious and can be prevented by avoiding direct contact with the infected person. The biggest cons of this disease are that there is no single vaccine to prevent or cure its virus.
There are mainly two stages involved in this. Stage one starts just with the infection which seldom comes with any symptoms. Hence it is left for late treatment which results in liver disease. Now after the advancement in medical field the treatment is possible and is effective.
To help these patients Star medicals works to get more effective and affordable medication so that the duration and efficacy of the treatment can be improved
Commonly sold under the name of Daklinza, Dacalatasvir is the medicine which is prescribed to cure chronic hepatitis C virus (HCV) genotypes 1 and 3 infection and is mostly taken along with sofosbuvir or the HCV protease inhibitor asunaprevir and ribavirin. Decalatasvir is a new direct- acting antiviral drug that targets different steps of the Hepatitis C Virus lifecycle. How it works? Decalatasvir interferes with the protein with the help of which the virus reproduces, hence curbing its chance to spread any further in the body. It is strictly advised to take Dacalatasvir only with sofosbuvir, hence if a patient discontinues with sofosbuvir permanently, then he should definitely avoid dacalatasvir.
A safe and well tolerated pill to cure Hepatitis C, Elbasvir and Grazoprevir is a one- pill- once a day option for the treatment of genotype 1 or 4 infections. The presence of amino acid 28, 30, 31 or 93 substitutes requires the additional intake of ribavirin for the pill to work effectively and also an extended therapy from 12 to 16 weeks. It is oral fixed dose combination of NS5A replication complex inhibitor and a later generation HCV protease inhibitor. If we look at the activity against the HCV genotypes, these are better than the earlier generation protease inhibitors. Further, it is a result of the failures from the first- generation protease inhibitors.
Glecaprevir – pibrentasvir is the first pangenotypic NS3/ 4A protease inhibitor- NS5A inhibitor combination is a better option to cure the chronic hepatitis C as it gives majority of patients a ribavirin free option unlike the other medicines. The drug is not suitable for the patients with decompensated cirrhosis because of the presence of the protease inhibitor. Clinical reports have shown 98-100% positive response rate amongst patients with genotypes 1, 2, 5 and 6. This is the least expensive treatment of Hepatitis C with lesser side effects.
This one-pill fixed-dose of a combination of Ledipasvir and Sofosbuvir is the most effective options for treating genotypes 1, 4, 5 and 6 Hep-C infection – as approved by the FDA. Hepatitis C virus BS5B polymerase is responsible for mediating HCV RNA replication and Sofosbuvir is a simple analog inhibitor of the same which, when combined with Ledipasvir, gives a revolutionary treatment drug with minimal side effects.
Technivie is generally used with ribavirin for improving the chances of getting cured and provides an option for patients who have compensated cirrhosis. The symptoms of cirrhosis in such patients are not visible but there is a considerable scarring on the inner lining of the liver. This regimen is one-a-day all-oral treatment option which minimizes the pill burden on patients which is brought in by the so-called directly active antiviral options.
An all-oral regimen, this combination can be a bit chunky for the patients and is recommended to only those who have compensated cirrhosis or a mild scarring inside the liver. A serious alternative to injections, Ritonavir, Paritaprevir, Ombitasvir, with Dasabuvir is helpful for patients with genotype 1a and 1b infections [with compensated cirrhosis] – patients with cirrhosis can cause severe damage to their liver with this combination.
Both Olysio and Sovaldi can be used together. They have provided an excellent option/alternative to the patients suffering from the genotype 1 HCV. Combination of the two has created a less extensive interaction between the drugs – it is also well tolerated as compared to the first-gen protease inhibitors. The previous combinations are not recommended because of the time it took for the treatment to get finalized and also due to the high toxicity levels.
This is arguably the most interferon-free combination available for the treatment of HCV genotypes 1 to 6. For patients suffering from genotype 3, Epclusa provides a single-pill option which can be taken without combining with ribavirin. If the patient has severe cirrhosis, the regimen can be taken with ribavirin but not in cases involving compensated cirrhosis. Eplusa is said to remove the Hep-C virus
Vosevi contains medications from three HCV antiviral classes. When a triple DAA [direct acting antiviral] works for patients who have suffered treatment failure, a dual therapy with sofosbuvir and velpatasvir works for all genotype 1 patients, and more effectively. This combination works best for the patients who have taken some treatments before and are suffering from compensated or severe cirrhosis. Vosevi is approved by the FDA for the treatment of adults with chronic HCV.